LCAR G08
Alternative Names: LCAR-G08; LCAR-G08 CAR T-cellsLatest Information Update: 05 Mar 2024
At a glance
- Originator Nanjing Legend Biotech
- Developer Nanjing Legend Biotech; Peking University
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastrointestinal cancer
Most Recent Events
- 09 Jan 2024 Phase-I clinical trials in Gastrointestinal cancer (Late-stage disease, Metastatic disease, In adults, In the elderly) in China (Infusion) (NCT06197178)
- 09 Jan 2024 Preclinical trials in Gastrointestinal cancer in China (Infusion), prior to January 2024